Retrospective Analysis of Adoptive TIL Therapy plus Anti-PD1 Therapy in Patients with Chemotherapy-Resistant Metastatic Osteosarcoma

Figure 6

Univariate analyses of more infusion of TIL numbers and CD8⁺TIL percentage and less infusion of CD8⁺PD1⁺TIL percentage and CD4⁺FoxP3⁺TIL percentage based on PFS and OS. (a) The PFS curve of patients, A: patients with more TIL numbers (, blue line) and less TIL numbers (, red line); B: patients with more CD8⁺TIL (≥60%, blue line) and less CD8⁺TIL (<60%, red line); C: patients with more CD8⁺PD1⁺TIL (≥10%, blue line) and less CD8⁺PD1⁺TIL (<10%, red line); D: patients with more CD4⁺FoxP3⁺TIL (≥20%, blue line) and less CD4⁺FoxP3⁺TIL (<20%, red line). (b) The OS curve of patients, A: patients with more TIL numbers (, blue line) and less TIL numbers (, red line); B: patients with more CD8⁺TIL (≥60%, blue line) and less CD8⁺TIL (<60%, red line); C: patients with more CD8⁺PD1⁺TIL (≥10%, blue line) and less CD8⁺PD1⁺TIL (<10%, red line); D: patients with more CD4⁺FoxP3⁺TIL (≥20%, blue line) and less CD4⁺FoxP3⁺TIL (<20%, red line).

(a)

(b)